A Phase 3 interventional study of Dasiglucagon and Glucagon in Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 1 site in Japan. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing dasiglucagon in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. dasiglucagon · Diabetes Mellitus, Type 1.
Among the 12 studies testing dasiglucagon in Diabetes Mellitus, Type 1, this one is the 5th largest by enrollment, is the only one that started in 2024, is one of 6 in phase 3, and was the 12th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →None of the 12 studies testing dasiglucagon in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →
dasiglucagon: first FDA approval 2021 (ZEGALOGUE), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 7
First in 2016; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is close to the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 31 across the 12 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 6 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S: 2 open now, 5 under way, 1 of them phase 3. Of 220 finished, 33 (15%) have results posted.
Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 104th largest by enrollment of the 149 interventional ones that give a count, is one of 2 that started in 2024, is one of 54 in phase 3, and was the 217th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 1 studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing dasiglucagon in Diabetes Mellitus, Type 1, from their registry updates:
Among Novo Nordisk A/S’s 226 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
This study will be looking to confirm the effect of dasiglucagon when compared with glucagon for treating very low blood sugar levels in Asian adults with T1D and the effect of dasiglucagon in Japanese adolescents with T1D. This study wants to demonstrate that dasiglucagon can raise low blood sugar levels just as well as glucagon. Participants will get dasiglucagon and glucagon. In which treatment order participants get study medicines (dasiglucagon and glucagon) is decided by chance. Dasiglucagon is a new medicine, but doctors can prescribe it in the US as it is approved there. Doctors can prescribe glucagon in multiple countries including Japan as an approved medicine. The study will last for about 17 weeks. Participant cannot be in the study if the study doctor thinks that there are risks for participants health. Women cannot take part if pregnant, breast-feeding, plan to get pregnant, during the study period, or not using adequate contraceptive methods. For man: if participant have sex, participant and his partner must use an adequate birth control method during the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Adults: Age 18-75 years (both inclusive):
For Adolescents: Age 12-15 years (both inclusive).
For adolescents: Body weight greater than or equal to (≥) 33.4 kilograms (kg).
Exclusion Criteria:
As declared by the participant or in the medical records.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single subcutaneous (s.c.) injection of dasiglucagon in first dosing visit then a single intra-mascular (i.m.) injection of glucagon in next dosing visit.
Drug: Dasiglucagon
Participants will receive a single i.m. injection of glucagon in first dosing visit then a single s.c. injection of dasiglucagon in next dosing visit.
Drug: Dasiglucagon · Drug: Glucagon
Participants will receive a single s.c. injection of dasiglucagon.
Drug: Dasiglucagon
Participants will receive s.c. injection of dasiglucagon.
Participants will receive i.m. injection of glucagon.
Time to Plasma Glucose (PG) Recovery in Adults: First Increase in PG of ≥20 mg/dL (1.1 mmol/L) From Baseline
This outcome measure reported time to PG recovery in Asian Japanese adults. PG recovery was defined as the first increase in PG of greater than or equal to (≥) 20 milligrams per deciliter (mg/dL) (1.1 millimoles per liter \[mmol/L\]) from baseline. Time to PG recovery was derived using linear interpolation between the last observed time point before recovery and the first observed time point after recovery, based on actual sampling time points with time zero as time of IMP injection.
Time frame: Baseline (Day 1), Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 90 minutes after IMP injection
Time to Plasma Glucose Recovery in Adolescents: First Increase in PG of ≥20 mg/dL (1.1 mmol/L) From Baseline (Japanese Adolescent Cohort Only)
This outcome measure reported time to PG recovery in adolescents Japanese population. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline. Time to PG recovery was derived using linear interpolation between the last observed time point before recovery and the first observed time point after recovery, based on actual sampling time points with time zero as time of IMP injection.
Time frame: Baseline (Day 1), Visit 2-Day 1 (Day 1): 0 to 90 minutes after IMP injection
Number of Participants Achieving PG Recovery Within 30 Minutes After IMP Injection (Yes/No)
This outcome measure reported number of participants achieving PG recovery within 30 minutes after IMP injection in adults and adolescents population arms, in terms of 'Yes' and 'No'. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline.
Time frame: Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 30 minutes after IMP injection
Number of Participants Achieving PG Recovery Within 20 Minutes After IMP Injection (Yes/No)
This outcome measure reported number of participants achieving PG recovery within 20 minutes after IMP injection in adults and adolescents population arms, in terms of 'Yes' and 'No'. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline.
Time frame: Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 20 minutes after IMP injection
Number of Participants Achieving PG Recovery Within 15 Minutes After IMP Injection (Yes/No)
This outcome measure reported number of participants achieving PG recovery within 15 minutes after IMP injection in adults and adolescents population arms, in terms of 'Yes' and 'No'. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline.
Time frame: Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 15 minutes after IMP injection
Change From Baseline in Plasma Glucose at 15 Minutes After IMP Injection
This outcome measure reports change from baseline in plasma glucose at 15 minutes after IMP injection for all participants in adults and adolescents arms.
Time frame: Baseline (Day 1), Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): at 15 minutes after IMP injection
Change From Baseline in Plasma Glucose at 20 Minutes After IMP Injection
This outcome measure reports change from baseline in plasma glucose at 20 minutes after IMP injection for all participants in adults and adolescents arms.
Time frame: Baseline (Day 1), Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): at 20 minutes after IMP injection
AUC0-30min: Area Under the Plasma Dasiglucagon Concentration Time Curve From 0 to 30 Minutes After IMP Injection
This outcome measure reported area under the plasma dasiglucagon concentration (AUC) time curve using the linear trapezoidal technique based on observed values and actual measurement times from 0 to 30 minutes (AUC0-30min) after IMP injection was administered in adult and adolescent participants in each reported arms.
Time frame: Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): Predose: 0 minute, Post-dose: 5, 15, 20, 25, and 30 minutes (From 0 to 30 minutes after IMP injection)
Cmax: Maximum Observed Plasma Dasiglucagon Concentration
This outcome measure reported maximum observed plasma dasiglucagon concentration (Cmax) after IMP injection was administered in adult and adolescent participants in each reported dasiglucagon arms.
Time frame: Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): Predose: 0 minute, Post-dose: 5, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 210, 300 minutes (From 0 to 5 hours after IMP injection)
Number of Adverse Events (AEs) for All Participants in Each Arms
This outcome measure reported Number of adverse events (AEs) for all participants in adults and adolescents arms. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of IMP, whether or not considered related to the IMP. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an IMP.
Time frame: From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 28 days after IMP injection
Number of Hypoglycaemic Episodes for All Participants in Each Arms
This outcome measure reports number of hypoglycaemic episodes for all participants in adults and adolescents arms. Hypoglycaemic episode is measured in terms of PG (blood or urine ketones were measured). Hypoglycaemia is defined as a decline in PG to below 70 mg/dL (3.9 mmol/L). Classification of hypoglycaemia (Level; Glycaemic criteria; Description) are as follows: 1) - Hypoglycaemia alert value (level 1); \<3.9 mmol/L (70 mg/dL) and ≥3.0 mmol/L (54 mg/dL); Sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy. 2) Clinically significant hypoglycaemia; \< 3.0 mmol/L (54 mg/dL); Sufficiently low to indicate serious, clinically important hypoglycaemia (level 2). 3) Severe hypoglycaemia (level 3); No specific glucose threshold; Hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery.
Time frame: From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 12 hours after IMP injection.
The study was conducted at 1 site in Japan.
| Milestone | Glucagon/Dasiglucagon (Adults) | Dasiglucagon/Glucagon (Adults) | Dasiglucagon (Adolescents) |
|---|---|---|---|
| Started | 17 | 17 | 4 |
| Exposed to investigational medicinal product (imp) | 16 | 17 | 4 |
| Full analysis set (fas) | 16 | 17 | 4 |
| Safety analysis set (sas) | 16 | 17 | 4 |
| Completed | 16 | 17 | 4 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Milestone | Glucagon/Dasiglucagon (Adults) | Dasiglucagon/Glucagon (Adults) | Dasiglucagon (Adolescents) |
|---|---|---|---|
| Started | 16 | 17 | 4 |
| Completed | 16 | 17 | 4 |
| Not completed | 0 | 0 | 0 |
| Milestone | Glucagon/Dasiglucagon (Adults) | Dasiglucagon/Glucagon (Adults) | Dasiglucagon (Adolescents) |
|---|---|---|---|
| Started | 16 | 17 | 0 |
| Completed | 16 | 17 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Glucagon/Dasiglucagon (Adults) | Dasiglucagon/Glucagon (Adults) | Dasiglucagon (Adolescents) |
|---|---|---|---|
| Started | 16 | 17 | 0 |
| Completed | 16 | 17 | 0 |
| Not completed | 0 | 0 | 0 |
This outcome measure reported time to PG recovery in Asian Japanese adults. PG recovery was defined as the first increase in PG of greater than or equal to (≥) 20 milligrams per deciliter (mg/dL) (1.1 millimoles per liter \[mmol/L\]) from baseline. Time to PG recovery was derived using linear interpolation between the last observed time point before recovery and the first observed time point after recovery, based on actual sampling time points with time zero as time of IMP injection.
| Minutes | Dasiglucagon (Adults) | Glucagon (Adults) |
|---|---|---|
| Time to Plasma Glucose (PG) Recovery in Adults: First Increase in PG of ≥20 mg/dL (1.1 mmol/L) From Baseline | 8.72 ± 1.90 | 8.16 ± 1.68 |
This outcome measure reported time to PG recovery in adolescents Japanese population. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline. Time to PG recovery was derived using linear interpolation between the last observed time point before recovery and the first observed time point after recovery, based on actual sampling time points with time zero as time of IMP injection.
| Minutes | Dasiglucagon (Adolescents) |
|---|---|
| Time to Plasma Glucose Recovery in Adolescents: First Increase in PG of ≥20 mg/dL (1.1 mmol/L) From Baseline (Japanese Adolescent Cohort Only) | 7.22 ± 0.87 |
This outcome measure reported number of participants achieving PG recovery within 30 minutes after IMP injection in adults and adolescents population arms, in terms of 'Yes' and 'No'. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline.
| Participants | Dasiglucagon (Adults) | Glucagon (Adults) | Dasiglucagon (Adolescents) |
|---|---|---|---|
| Yes | 33 | 33 | 4 |
| No | 0 | 0 | 0 |
This outcome measure reported number of participants achieving PG recovery within 20 minutes after IMP injection in adults and adolescents population arms, in terms of 'Yes' and 'No'. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline.
| Participants | Dasiglucagon (Adults) | Glucagon (Adults) | Dasiglucagon (Adolescents) |
|---|---|---|---|
| Yes | 33 | 33 | 4 |
| No | 0 | 0 | 0 |
This outcome measure reported number of participants achieving PG recovery within 15 minutes after IMP injection in adults and adolescents population arms, in terms of 'Yes' and 'No'. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline.
| Participants | Dasiglucagon (Adults) | Glucagon (Adults) | Dasiglucagon (Adolescents) |
|---|---|---|---|
| Yes | 33 | 33 | 4 |
| No | 0 | 0 | 0 |
This outcome measure reports change from baseline in plasma glucose at 15 minutes after IMP injection for all participants in adults and adolescents arms.
| mg/dL | Dasiglucagon (Adults) | Glucagon (Adults) | Dasiglucagon (Adolescents) |
|---|---|---|---|
| Change From Baseline in Plasma Glucose at 15 Minutes After IMP Injection | 48.09 ± 14.38 | 51.21 ± 11.72 | 51.50 ± 4.51 |
This outcome measure reports change from baseline in plasma glucose at 20 minutes after IMP injection for all participants in adults and adolescents arms.
| mg/dL | Dasiglucagon (Adults) | Glucagon (Adults) | Dasiglucagon (Adolescents) |
|---|---|---|---|
| Change From Baseline in Plasma Glucose at 20 Minutes After IMP Injection | 63.35 ± 17.07 | 65.30 ± 13.38 | 69.00 ± 9.02 |
This outcome measure reported area under the plasma dasiglucagon concentration (AUC) time curve using the linear trapezoidal technique based on observed values and actual measurement times from 0 to 30 minutes (AUC0-30min) after IMP injection was administered in adult and adolescent participants in each reported arms.
| h*pmol/L | Dasiglucagon (Adults) | Dasiglucagon (Adolescents) |
|---|---|---|
| AUC0-30min: Area Under the Plasma Dasiglucagon Concentration Time Curve From 0 to 30 Minutes After IMP Injection | 346.39 ± 46.22 | NA ± NA |
This outcome measure reported maximum observed plasma dasiglucagon concentration (Cmax) after IMP injection was administered in adult and adolescent participants in each reported dasiglucagon arms.
| pmol/L | Dasiglucagon (Adults) | Dasiglucagon (Adolescents) |
|---|---|---|
| Cmax: Maximum Observed Plasma Dasiglucagon Concentration | 1230.24 ± 33.47 | NA ± NA |
This outcome measure reported Number of adverse events (AEs) for all participants in adults and adolescents arms. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of IMP, whether or not considered related to the IMP. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an IMP.
| Events | Dasiglucagon (Adults) | Glucagon (Adults) | Dasiglucagon (Adolescents) |
|---|---|---|---|
| Number of Adverse Events (AEs) for All Participants in Each Arms | 29 | 18 | 3 |
This outcome measure reports number of hypoglycaemic episodes for all participants in adults and adolescents arms. Hypoglycaemic episode is measured in terms of PG (blood or urine ketones were measured). Hypoglycaemia is defined as a decline in PG to below 70 mg/dL (3.9 mmol/L). Classification of hypoglycaemia (Level; Glycaemic criteria; Description) are as follows: 1) - Hypoglycaemia alert value (level 1); \<3.9 mmol/L (70 mg/dL) and ≥3.0 mmol/L (54 mg/dL); Sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy. 2) Clinically significant hypoglycaemia; \< 3.0 mmol/L (54 mg/dL); Sufficiently low to indicate serious, clinically important hypoglycaemia (level 2). 3) Severe hypoglycaemia (level 3); No specific glucose threshold; Hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery.
| Episodes | Dasiglucagon (Adults) | Glucagon (Adults) | Dasiglucagon (Adolescents) |
|---|---|---|---|
| Hypoglycaemia alert value (level 1) | 0 | 2 | 0 |
| Clinically significant hypoglycaemia (level 2) | 0 | 1 | 1 |
| Severe hypoglycaemia (level 3) | 1 | 0 | 0 |
| Severe (level 3) or clinically significant (level 2) hypoglycaemia | 1 | 1 | 1 |
Collected over From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 28 days after IMP injection. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Glucagon (Adults) | 0/33 (0%) | 0/33 (0%) | 9/33 (27.3%) |
| Dasiglucagon (Adults) | 0/33 (0%) | 0/33 (0%) | 16/33 (48.5%) |
| Dasiglucagon (Adolescents) | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Total | 0/37 (0%) | 0/37 (0%) | 21/37 (56.8%) |
| Event | Glucagon (Adults) | Dasiglucagon (Adults) | Dasiglucagon (Adolescents) | Total |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 9/33 | 15/33 | 2/4 | 20/37 |
| VomitingGastrointestinal disorders | 8/33 | 13/33 | 1/4 | 16/37 |
| DiarrhoeaGastrointestinal disorders | 1/33 | 1/33 | 0/4 | 2/37 |
Baseline analysis was conducted on FAS population. FAS (adults)-All randomized adult participants who received at least one dose of IMP; FAS (adolescents)-All adolescent participants who received one dose of IMP.
| Age, Continuous(Years) | Dasiglucagon and Glucagon (Adults) | Dasiglucagon (Adolescents) | Total |
|---|---|---|---|
| Mean | 40.03 ± 11.66 | 13.75 ± 0.96 | 37.2 ± 13.8 |
| Sex: Female, Male(Participants) | Dasiglucagon and Glucagon (Adults) | Dasiglucagon (Adolescents) | Total |
|---|---|---|---|
| Female | 12 | 2 | 14 |
| Male | 21 | 2 | 23 |
| Ethnicity (NIH/OMB)(Participants) | Dasiglucagon and Glucagon (Adults) | Dasiglucagon (Adolescents) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 33 | 4 | 37 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Dasiglucagon and Glucagon (Adults) | Dasiglucagon (Adolescents) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 33 | 4 | 37 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Sep 2024 to primary completion in Jul 2025, 10 months.
Results were first posted in Nov 2026, 1 year 3 months after primary completion.
Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 10 months is below that.
Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dasiglucagon